HealthEconomics.Com

Connected. Community.

  • facebook
  • linkedin
  • twitter
  • vimeo
  • rss
  • News
  • Jobs
    • HE Jobs Portal
    • View all Jobs
    • Post a Job
  • Value, Evidence & Access Marketplace
    • About the Marketplace
    • Visit the Marketplace
    • On-demand Webinar
    • Find Out More
  • Industry Events
    • Conferences
    • Webinars
    • HealthEconomics.Com On-demand Webinars
    • Webinar Archives
  • Newsletters
    • Subscribe
    • View All
  • Blog
  • Resources
    • Value Communication
    • Free Marketing Consultation!
    • The Future of Print Medical Journals: How to Stay Relevant
    • Be a Better Writer
    • White Papers
    • Education Resources
    • Syndicated Reports
    • Books
    • Databases
    • Blogs
      • HE-Artists
      • Podcasts
Home » News » CMS Issues Lowest Part D Premium Since 2013: AHIP Warns Rebate Rule Could Impact This

CMS Issues Lowest Part D Premium Since 2013: AHIP Warns Rebate Rule Could Impact This

CMS has announced the average basic Part D premium for 2021 will be $30.50. This presents a slight uptick from the 2020 average basic Part D premium when premiums were around $30. Premium savings over the past three years have amounted to $1.9 billion, according to CMS, and savings are due to increased plan competition.

“In Medicare Part D, beneficiaries choose the prescription drug plan that best meets their needs, and plans have to improve quality and lower costs to attract beneficiaries. This competitive dynamic sets up clear incentives that drive towards value,” the July 29 press release from CMS.gov explained.

The Part D Payment Modernization Model, implemented in 2019 by CMS, incentivized lower drug prices as payers took on higher risk for beneficiaries in Part D’s catastrophic phase.  In 2021, nine plans in 4 states will participate in this Model.

America’s Health Insurance Plans (AHIP) warns that the rebate rule could affect the continuing savings on out-of-pocket healthcare costs. Last week, Trump signed three executive orders that placed restrictions on pharmacy benefit managers and sought to heighten drug importations. Through these measures, the executive orders aimed to lower drug prices. AHIP has argued, using CMS statistics, that these executive orders would instead cause Medicare premiums to rise by 25%, and increase drug spending in Medicare by almost $200 billion, and contribute about $100B toward bailing out the pharmaceutical industry.

Read more.

(Source:  Waddill K, Health Payer Intelligence, July 31, 2020)



You might also be interested in:

  • Amalgam Rx™ and AWS Collaborate to Accelerate and Simplify… 07/19/2021
  • Exploring Climate Change Through the Lens of Health Equity 05/25/2022
  • OM1 Launches Real-World Data Network for Neuroscience and… 03/31/2022
  • ICER Meets With FDA, EMA, and FDA to Discuss RWE Procedures 10/12/2021
  • Call for Papers: Essen Health Conference 02/21/2022
  • Telehealth Could Advance Value-based Care in the US 12/15/2021
  • Influential Usage of Big Data and Artificial Intelligence in… 09/07/2021

Advertise With Us!View All JobsPost a JobView Current NewsletterSubscribe to Newsletters
Webinar of the Week
Conference of the Week
Link of the Week

HealthEconomics.Com Jobs Portal

  • Manager, Statistical Analytics
  • Director / Senior Director, RWE
  • Research Analyst
  • Medical Writer
  • Associate Director/Director, Business Development
 
Syndicated Reports

Economic & Related Consulting Service Revenues World Report & Database

Healthcare Analytical Testing Services Market worth $9.8 billion by 2026 – Key Players are Eurofins Scientific, SGS S.A., Charles River Laboratories

Risk-Based Monitoring Software Market Worth $511 Million By 2025 – Growing Number Of Clinical Trials To Propel Market Growth

Real-World Evidence Solutions Market – Growth, Trends, COVID-19 Impact, and Forecasts (2021 – 2026)

 
White Papers

The Augmented Rep: A practical field force guide for the Omnichannel era

Rare Disease’s Star Turn

The Next Generation of Information Management

Risk Mitigation for Pharma Manufacturer Programs

HealthEconomics.Com

HealthEconomics.Com

  • News
  • Conferences
  • Reports
  • Jobs
  • Consulting
  • Newsletters
  • White Papers

More Links

  • Jobs
  • Education
  • Graduate Schools
  • Webinar Services

Support & Contact

  • Contact Us

About

  • About Us
  • Advertise
  • Webinar Services
  • HE Institute
  • Testimonials
  • Privacy Policy

Stay Connected

  • facebook
  • twitter
  • linkedin
  • pinterest
  • google-plus
  • youtube
  • rss

HealthEconomics.Com is the world’s most comprehensive and credible CONNECTED COMMUNITYTM that serves as the global link to the health economics & outcomes research (HEOR) and pharma market access stakeholder communities.

HEALTHECONOMICS HZ SMALL V2

HealthEconomics.Com is the world’s most comprehensive and credible CONNECTED COMMUNITYTM that serves as the global link to the health economics & outcomes research (HEOR) and pharma market access stakeholder communities, proving news, education, jobs, resources, policy updates, consulting, advertising, all available via website, newsletters, and social media.

© 2017 Health Economics. All rights reserved.

  • News
  • Jobs
    • HE Jobs Portal
    • View all Jobs
    • Post a Job
  • Value, Evidence & Access Marketplace
    • About the Marketplace
    • Visit the Marketplace
    • On-demand Webinar
    • Find Out More
  • Industry Events
    • Conferences
    • Webinars
    • HealthEconomics.Com On-demand Webinars
    • Webinar Archives
  • Newsletters
    • Subscribe
    • View All
  • Blog
  • Resources
    • Value Communication
    • Free Marketing Consultation!
    • The Future of Print Medical Journals: How to Stay Relevant
    • Be a Better Writer
    • White Papers
    • Education Resources
    • Syndicated Reports
    • Books
    • Databases
    • Blogs
      • HE-Artists
      • Podcasts